Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS) (ACTiMuS)
Primary Purpose
Progressive Multiple Sclerosis
Status
Unknown status
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
Early infusion of autologous marrow
Late infusion of autologous marrow
Sponsored by
About this trial
This is an interventional treatment trial for Progressive Multiple Sclerosis focused on measuring multiple sclerosis, progressive MS, stem cell, cell therapy, neurodegeneration, CNS repair
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of clinically-definite MS as defined by the McDonald criteria
- Aged 18 - 65 years.
- EDSS of 4.0 to 6 inclusive
- Disease duration >5 years
- Disease progression (increase in physical disability, not due to major relapse) in preceding year
- Signed, written informed consent
- Willing and able to comply with study visits according to protocol for the full study period
Exclusion Criteria:
- Pregnancy, breastfeeding or lactation
- History of autologous/allogenic bone marrow transplantation or peripheral blood stem cell transplant
- Bone marrow insufficiency
- History of lymphoproliferative disease or previous total lymphoid irradiation
- Immune deficiency
- Current or recent (<5 years) malignancy
- Chronic or frequent drug-resistant bacterial infections or presence of active infection requiring antimicrobial treatment
- Frequent and/or serious viral infection
- Systemic or invasive fungal disease within 2 years of entry to study
- Significant renal, hepatic, cardiac or respiratory dysfunction
- Contraindication to anaesthesia
- Bleeding or clotting diathesis
- Current or recent (within preceding 12 months) immunomodulatory therapy other than corticosteroid therapy
- Treatment with corticosteroids within the preceding three months
- Significant relapse within preceding 6 months
- Predominantly relapsing-remitting disease over preceding 12 months
- Radiation exposure in the past year other than chest / dental x-rays
- Previous claustrophobia
- The presence of any implanted metal or other contraindication to MRI
- Participation in another experimental study or treatment within the preceding 24 months
Sites / Locations
- Southmead HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Early infusion of autologous marrow
Late infusion of autologous marrow
Arm Description
Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
Outcomes
Primary Outcome Measures
Global evoked potential (GEP): mean change from time of marrow infusion to end of study
Multimodal evoked potentials will be examined at 0, 6, 12, 18 and 24 months. Evoked potential abnormalities will be quantified according to a 4-point graded ordinal score modified from Leocani et al (JNNP 2006, 77:1030-1035) (0=normal; 1=increased latency; 2=increased latency and abnormal amplitude; 3=absent).
The recording of the evoked potentials shall be in accordance with the Guidelines of the International Federation of Clinical Neurophysiology and analysis will be performed using standard methods. Electrophysiological responses shall be considered abnormal if they exceed 2.5 standard deviations of the normal values or cannot be detected.
Secondary Outcome Measures
Safety
Evaluation of number and nature of adverse events
Expanded disability status scale
Time to EDSS progression of at least one point from a baseline EDSS of 4.0, 4.5 or 5.0 or at least 0.5 points from a baseline EDSS ≥5.5
Multiple sclerosis impact scale (MSIS-29)
Mean change from baseline to end of study on the patient-based MSIS-29 scale
Multiple sclerosis functional composite (MSFC)
Mean change on MSFC score from baseline to final visit
MRI head and cord
The secondary MRI outcome measures will relate to 1) lesion load, 2) atrophy measures both of the brain and of cross-sectional area of the spinal cord, and changes in mean diffusivity.
Exploratory analysis of the resting-state fMRI data will investigate correlations between network patterns and 'strength' of networks connectivity from the resting-state fMRI with classifications revealed by the various evoked potential studies
Optical coherence tomography
Measurement of retinal nerve fibre layer thickness and macular volume
Full Information
NCT ID
NCT01815632
First Posted
March 19, 2013
Last Updated
June 26, 2018
Sponsor
North Bristol NHS Trust
Collaborators
Bristol Royal Hospital for Children, University of Bristol, University of Nottingham, NHS Blood and Transplant, Kenneth and Claudia Silverman Family Foundation, Multiple Sclerosis Trust, Medical Research Council, Rosetrees Trust, Catholic Bishops of England and Wales, Friends of Frenchay
1. Study Identification
Unique Protocol Identification Number
NCT01815632
Brief Title
Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
Acronym
ACTiMuS
Official Title
Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 2014 (undefined)
Primary Completion Date
October 2019 (Anticipated)
Study Completion Date
October 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
North Bristol NHS Trust
Collaborators
Bristol Royal Hospital for Children, University of Bristol, University of Nottingham, NHS Blood and Transplant, Kenneth and Claudia Silverman Family Foundation, Multiple Sclerosis Trust, Medical Research Council, Rosetrees Trust, Catholic Bishops of England and Wales, Friends of Frenchay
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Multiple sclerosis - MS - affects 1.3m people worldwide, costing the European Union economy €9 billion/year, through both direct and indirect consequences of progressive disability. Despite the usual relapsing-remitting presentation, over 80% of patients develop progressive disability; 40% require a wheelchair within 10 years of diagnosis. At present, there are no treatments that reverse, halt or even slow progressive disability in MS.
The investigators recently completed one of the first feasibility/safety trials in the world of reparative bone marrow cell therapy in 6 patients with longstanding MS (www.nature.com/clpt/journal/v87/n6/full/clpt201044a.html). Safety was confirmed, and intensive repeated tests on the patients measuring nerve conduction in various pathways in the brain and in the spinal cord showed statistically significant improvements at 12 months in every patient. While highly preliminary and involving only a very small number of patients, these results at least raise the possibility of a significant (though very partial) underlying repair effect within the damaged nervous system.
The investigators believe this urgently requires further testing - both to accelerate benefit for patients, and to begin improving therapeutic efficacy. The investigators therefore propose a programme of translational and clinical stem cell research, aiming (1) to continue translation with a phase two controlled trial of bone marrow cells in patients with longstanding MS; and (2) to explore in parallel the potential mechanisms of action, by studying bone marrow cells from treated patients and control subjects, aiming to establish which of the various relevant bone marrow subpopulations contribute to efficacy, and which particular reparative mechanism(s) are important. The investigators hope these studies will not only confirm the therapeutic benefit of this approach, but also provide the basis for improving the magnitude and impact of this novel and exciting treatment modality.
Detailed Description
The primary objective is to determine whether autologous bone marrow (BM) (ie taken from the patients themselves rather than from a BM donor) cell therapy is truly beneficial in chronic multiple sclerosis - as our small, uncontrolled phase 1 trial suggested (www.nature.com/clpt/journal/v87/n6/full/clpt201044a.html).
The investigators also aim to answer the following questions:
Do BM mesenchymal stem cells from patients with MS differ in the range or extent of reparative and neuroprotective properties from those from control individuals?
What reparative and neuroprotective properties do BM stem cell subpopulations other than mesenchymal stem cells possess, and do these differ between MS patients and controls?
Can BM stem cell subpopulations be isolated from blood samples from MS patients following treatment, and, if so, for how long?
Bone marrow contains stem cells capable of replacing all the cells in the blood. Recently, bone marrow has been found to contain cells capable of replacing cells in tissues and organs other than blood. In addition, infusion of bone marrow-derived cells has been shown to have significant effects on the immune system and to promote the survival of central nervous system cells under toxic conditions. These properties are of considerable interest to those working to develop cell-based therapies for neurodegenerative disease.
The potential of such cells to aid repair in multiple sclerosis (MS) has been examined in experimental models of MS. Myelin is the substance that insulates neurons within the central nervous system and is attacked in MS. Infusion of adult bone marrow cells into a vein aids myelin repair (remyelination) in these models of MS. Recently, the investigators performed a small pilot study to examine the effects of harvesting bone marrow from MS patients and infusing this back into each patient's vein. This was well tolerated and no significant adverse events were encountered. Electrophysiological studies appeared to show some improvement but, given the small numbers of participants in the phase 1 trial, no definitive conclusion can be made regarding this.
The current study seeks to address the question of whether genuine improvements in neurophysiological tests are seen in MS patients with progressive disease following infusion of bone marrow.
A prospective, randomised, double-blind, placebo-controlled, stepped wedge design will be employed at a single centre (Bristol, UK). Eighty patients with progressive MS will be recruited; 60 will have secondary progressive disease (SPMS) but a subset (n=20) will have primary progressive disease (PPMS). Participants will be randomised to either early (immediate) or late (1 year) intravenous infusion of autologous, unfractionated bone marrow. The placebo intervention is infusion of autologous blood. The primary outcome measure is global evoked potential derived from multimodal evoked potentials. Secondary outcome measures include adverse event reporting, clinical (EDSS and MSFC) and self-assessment (MSIS-29) rating scales, optical coherence tomography (OCT) as well as brain and spine MRI. Participants will be followed up for a further year following the final intervention. Outcomes will be analyzed on an intention-to-treat basis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Progressive Multiple Sclerosis
Keywords
multiple sclerosis, progressive MS, stem cell, cell therapy, neurodegeneration, CNS repair
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Early infusion of autologous marrow
Arm Type
Experimental
Arm Description
Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
Arm Title
Late infusion of autologous marrow
Arm Type
Experimental
Arm Description
Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
Intervention Type
Other
Intervention Name(s)
Early infusion of autologous marrow
Intervention Description
Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
Intervention Type
Other
Intervention Name(s)
Late infusion of autologous marrow
Intervention Description
Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
Primary Outcome Measure Information:
Title
Global evoked potential (GEP): mean change from time of marrow infusion to end of study
Description
Multimodal evoked potentials will be examined at 0, 6, 12, 18 and 24 months. Evoked potential abnormalities will be quantified according to a 4-point graded ordinal score modified from Leocani et al (JNNP 2006, 77:1030-1035) (0=normal; 1=increased latency; 2=increased latency and abnormal amplitude; 3=absent).
The recording of the evoked potentials shall be in accordance with the Guidelines of the International Federation of Clinical Neurophysiology and analysis will be performed using standard methods. Electrophysiological responses shall be considered abnormal if they exceed 2.5 standard deviations of the normal values or cannot be detected.
Time Frame
Entry and every 6 months for 2 years
Secondary Outcome Measure Information:
Title
Safety
Description
Evaluation of number and nature of adverse events
Time Frame
Continuous throughout study period (2 years)
Title
Expanded disability status scale
Description
Time to EDSS progression of at least one point from a baseline EDSS of 4.0, 4.5 or 5.0 or at least 0.5 points from a baseline EDSS ≥5.5
Time Frame
At entry then 6 weeks, 6 months and 1 year after each infusion
Title
Multiple sclerosis impact scale (MSIS-29)
Description
Mean change from baseline to end of study on the patient-based MSIS-29 scale
Time Frame
At entry then 6 weeks, 6 months and 1 year after each infusion
Title
Multiple sclerosis functional composite (MSFC)
Description
Mean change on MSFC score from baseline to final visit
Time Frame
At entry then 6 weeks, 6 months and 1 year after each infusion
Title
MRI head and cord
Description
The secondary MRI outcome measures will relate to 1) lesion load, 2) atrophy measures both of the brain and of cross-sectional area of the spinal cord, and changes in mean diffusivity.
Exploratory analysis of the resting-state fMRI data will investigate correlations between network patterns and 'strength' of networks connectivity from the resting-state fMRI with classifications revealed by the various evoked potential studies
Time Frame
At entry, 1 year and 2 years post-harvest
Title
Optical coherence tomography
Description
Measurement of retinal nerve fibre layer thickness and macular volume
Time Frame
Entry, 1 year and 2 years post-harvest
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of clinically-definite MS as defined by the McDonald criteria
Aged 18 - 65 years.
EDSS of 4.0 to 6 inclusive
Disease duration >5 years
Disease progression (increase in physical disability, not due to major relapse) in preceding year
Signed, written informed consent
Willing and able to comply with study visits according to protocol for the full study period
Exclusion Criteria:
Pregnancy, breastfeeding or lactation
History of autologous/allogenic bone marrow transplantation or peripheral blood stem cell transplant
Bone marrow insufficiency
History of lymphoproliferative disease or previous total lymphoid irradiation
Immune deficiency
Current or recent (<5 years) malignancy
Chronic or frequent drug-resistant bacterial infections or presence of active infection requiring antimicrobial treatment
Frequent and/or serious viral infection
Systemic or invasive fungal disease within 2 years of entry to study
Significant renal, hepatic, cardiac or respiratory dysfunction
Contraindication to anaesthesia
Bleeding or clotting diathesis
Current or recent (within preceding 12 months) immunomodulatory therapy other than corticosteroid therapy
Treatment with corticosteroids within the preceding three months
Significant relapse within preceding 6 months
Predominantly relapsing-remitting disease over preceding 12 months
Radiation exposure in the past year other than chest / dental x-rays
Previous claustrophobia
The presence of any implanted metal or other contraindication to MRI
Participation in another experimental study or treatment within the preceding 24 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Claire M Rice, MA MRCP PhD
Phone
00 44 117 4146695
Email
claire.rice@nbt.nhs.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Neil J Scolding, PhD FRCP
Phone
00 44 117 4146694
Email
heather.williams@nbt.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil J Scolding, FRCP PhD
Organizational Affiliation
University of Bristol & North Bristol NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Southmead Hospital
City
Bristol
ZIP/Postal Code
BS10 5NB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neil J Scolding, FRCP PhD
First Name & Middle Initial & Last Name & Degree
Claire M Rice, MA MRCP PhD
12. IPD Sharing Statement
Citations:
PubMed Identifier
26467901
Citation
Rice CM, Marks DI, Ben-Shlomo Y, Evangelou N, Morgan PS, Metcalfe C, Walsh P, Kane NM, Guttridge MG, Miflin G, Blackmore S, Sarkar P, Redondo J, Owen D, Cottrell DA, Wilkins A, Scolding NJ. Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial. Trials. 2015 Oct 14;16:463. doi: 10.1186/s13063-015-0953-1.
Results Reference
derived
Learn more about this trial
Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
We'll reach out to this number within 24 hrs